Literature DB >> 11751390

Differential association of the codon 72 p53 and GSTM1 polymorphisms on histological subtype of non-small cell lung carcinoma.

G Liu1, D P Miller, W Zhou, S W Thurston, R Fan, L L Xu, T J Lynch, J C Wain, L Su, D C Christiani.   

Abstract

Traditionally, non-small cell lung cancer (NSCLC) has been evaluated as a unique entity in genotyping studies. However, recent biological data suggest that different NSCLC subtypes, specifically adenocarcinomas (AC) and squamous cell carcinomas (SCC), differentially alter cancer behavior. Several studies have associated a p53 polymorphism at codon 72 with NSCLC susceptibility. This study investigated whether different p53 genotypes altered the overall risk of developing AC versus SCC. Polymorphisms in metabolizing enzymes, together with prolonged exposure to tobacco carcinogens, can result in accumulation of DNA damage; these effects may potentiate the effects of subtle differences in p53 function. Thus, interactions between polymorphisms of p53 and either GSTM1 or GSTT1 were also evaluated. We analyzed 1168 incident lung cancer cases and 1256 control subjects using multiple logistic regression. Histological data were available for 1144 cases (98%): 585 with AC, 284 with SCC, and 275 with other histological subtypes (large cell, small cell, mixed, and other). An increase in the NSCLC risk posed by the p53 Pro allele (versus Arg/Arg) was seen in AC compared with controls [adjusted odds ratio (OR), 1.36; 95% confidence interval (CI), 1.1-1.7] but not in SCC (adjusted OR, 1.04; 95% CI, 0.8-1.4). Among AC and SCC cancer patients, individuals with the GSTM1-null genotype had an OR of 1.80 (95% CI, 1.1-2.8; case-only analysis) of having AC versus SCC if they also carried a p53 Pro allele. We conclude that different genotype combinations of p53 and GSTM1 increase the risk of developing specific histological subtypes of NSCLC.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11751390

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

1.  Association of p53 codon 72 polymorphism with prostate cancer: a meta-analysis.

Authors:  Yu Zhu; Jing Wang; Qian He; Jun-Qing Zhang
Journal:  Mol Biol Rep       Date:  2010-09-15       Impact factor: 2.316

2.  Genetic modifiers of carcinogen DNA adducts in target lung and peripheral blood mononuclear cells.

Authors:  Mi-Sun Lee; Li Su; Eugene J Mark; John C Wain; David C Christiani
Journal:  Carcinogenesis       Date:  2010-10-08       Impact factor: 4.944

3.  Assessment of cumulative evidence for the association between glutathione S-transferase polymorphisms and lung cancer: application of the Venice interim guidelines.

Authors:  Scott M Langevin; John P A Ioannidis; Paolo Vineis; Emanuela Taioli
Journal:  Pharmacogenet Genomics       Date:  2010-10       Impact factor: 2.089

4.  Synergistic effects of NAT2 slow and GSTM1 null genotypes on carcinogen DNA damage in the lung.

Authors:  Mi-Sun Lee; Li Su; David C Christiani
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05-25       Impact factor: 4.254

5.  Association between the TP53 polymorphisms and lung cancer risk: a meta-analysis.

Authors:  Xiang-Hua Ye; Zhi-Bin Bu; Jie Feng; Ling Peng; Xin-Biao Liao; Xin-Li Zhu; Xiao-Li Sun; Hao-Gang Yu; Dan-Fang Yan; Sen-Xiang Yan
Journal:  Mol Biol Rep       Date:  2013-11-23       Impact factor: 2.316

Review 6.  The association between TP53 Arg72Pro polymorphism and lung cancer susceptibility: evidence from 30,038 subjects.

Authors:  Qian Qiao; Weiguo Hu
Journal:  Lung       Date:  2013-04-18       Impact factor: 2.584

7.  p53 Pro72Arg polymorphism and prostate cancer in men of African descent.

Authors:  L Ricks-Santi; T Mason; V Apprey; C Ahaghotu; A McLauchlin; D Josey; G Bonney; G M Dunston
Journal:  Prostate       Date:  2010-12-01       Impact factor: 4.104

8.  P53 codon 72 polymorphism and lung cancer risk: evidence from 27,958 subjects.

Authors:  Chao Zhou; Hao Chen; An Wang
Journal:  Tumour Biol       Date:  2013-05-30

9.  P53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case-control studies.

Authors:  Shengming Dai; Chen Mao; Lijun Jiang; Guisheng Wang; Hongge Cheng
Journal:  Hum Genet       Date:  2009-04-09       Impact factor: 4.132

10.  Glutathione S-transferase GSTM1, GSTT1 and p53 codon 72 polymorphisms in human tumor cells.

Authors:  Masatsugu Ueda; Yao-Ching Hung; Yoshito Terai; Koji Kanda; Mikio Takehara; Hikari Yamashita; Hiroyuki Yamaguchi; Daisuke Akise; Masayuki Yasuda; Koji Nishiyama; Minoru Ueki
Journal:  Hum Cell       Date:  2003-12       Impact factor: 4.174

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.